


Claims


1. A compound of formula (I)



- that is 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.
2. A pharmaceutical composition comprising a compound according to claim 1, in combination with one or more pharmaceutically acceptable diluents or carriers.
 3. A compound of formula (I) according to any one of claims 1 to 2 for use as a medicament.
 4. A compound of formula (I) according to claim 1 or a pharmaceutical composition according to claim 2 for use in the treatment or prevention of a condition selected from:
COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis, allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis, rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma.
 5. Use of a compound of formula (I) according to claim 1 or a pharmaceutical formulation according to claim 2 for the manufacture of a medicament for the treatment or prevention of a condition selected from:
COPD (including chronic bronchitis and emphysema), asthma, paediatric

asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis,
allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis,
rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma.


6. A method of treatment of a condition selected from:
COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis,
allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis,
rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma which comprises administering to a subject an effective amount of a compound of formula (I) according to claim 1 or a pharmaceutical composition according to claim 2.
7. An intermediate of formula (II):



wherein LG₁ represents a leaving group;
or a protected derivate thereof.

Claims

1. A compound of formula (I)



that is 6-(2-((4-amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N,N*-bis(2-methoxyethyl)hex-5-ynamide or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.

2. A pharmaceutical composition comprising a compound according to claim 1, in combination with one or more pharmaceutically acceptable diluents or carriers.
3. A compound of formula (I) according to any one of claims 1 to 2 for use as a medicament.
4. A compound of formula (I) according to claim 1 or a pharmaceutical composition according to claim 2 for use in the treatment or prevention of a condition selected from:
COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis,
allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis,
rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma.
5. A compound of formula (I) according to claim 1 for use in the treatment or prevention of a respiratory disorder.
6. A compound of formula (I) for use according to claim 4 or 5 in combination with

one or more other active ingredients.

7. A compound of formula (I) for use according to claim 5 in combination with one of more other active ingredients selected from steroids, beta agonists, xanthines, musacarinic antagonists and p38 MAP kinase inhibitors.
8. A compound of formula (I) for use according to claim 5 in combination with a steroid selected from budesonide, beclomethasone dipropionate, fluticasone propionate, mometasone furoate and fluticasone furoate.
9. A compound of formula (I) for use according to claim 5 in combination with a beta agonist selected from terbutaline, salbutamol, salmeterol, formoterol and indacaterol.
10. A compound of formula (I) for use according to claim 5 in combination with a xanthine, wherein the xanthine is theophylline.
11. A compound of formula (I) for use according to claim 5 in combination with a musacarinic antagonist, wherein the musacarinic antagonist is ipratropium.
12. A compound of formula (I) for use according to claim 5 in combination with a p38 MAP kinase inhibitor.
13. A compound of formula (I) for use according to claim 3 in combination with an antiviral agent.
14. A compound of formula (I) for use according to claim 3 in combination with an antiviral agent selected from acyclovir, tamiflu, relenza and interferon.
15. Use of a compound of formula (I) according to claim 1 or a pharmaceutical formulation according to claim 2 for the manufacture of a medicament for the treatment or prevention of a condition selected from:
COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis,
allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis,
rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma.